RCT1213 / ReCerise Therapeutics - LARVOL DELTA

Gastrointestinal tumor-associated target: A first-in-class therapeutic monoclonal antibody (AACR 2026) - "Targeting TM4SF5 with RCT1213 alleviates TM4SF5-driven immunosuppression and restores innate effector function, resulting in robust anti-tumor activity in MSS-CRC models. These findings position TM4SF5 as an upstream immune-modulatory target and support RCT1213 as a first-in-class therapeutic candidate. IND-enabling studies are underway to advance RCT1213 into clinical development for MSS-CRC and other TM4SF5-expressing solid tumors."

Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CAFs • TM4SF5

ReCerise Therapeutics’ RCT1213 wins FDA orphan drug designation for liver cancer (Korea Biomedical Review) - "RCT1213 is designed to modulate the tumor microenvironment through a novel mechanism. As a first-in-class candidate, it is intended to offer immune modulation distinct from existing checkpoint inhibitors. Its activity has been observed in preclinical and early studies, including in models resistant to checkpoint inhibitors, supporting its potential as a treatment option."

Orphan drug • Hepatocellular Cancer

ADDING MULTIMEDIA ReCerise Signs New Research Collaboration Agreement towards Development of Innovative Treatment for Hepatocellular Carcinoma (Businesswire) - "ReCerise Therapeutics Inc...recently entered a research partnership with the National Cancer Centre Singapore ('NCCS') to develop innovative treatments utilizing multi-omics data analyses in hepatocellular carcinoma (HCC)...This collaboration will be conducted under the PLANet programme...'Through this joint research, we plan to conduct multi-faceted studies on the development potential of RCT1213, a hepatocellular carcinoma treatment candidate currently under development, by utilizing the various omics data and research database of Asian HCC patients at NCCS.' The research collaboration between these two parties is a research and development project funded by the Korean government and is subject to the management and supervision of the Korea Evaluation Institute of Industrial Technology (KEIT)."

Commercial • Hepatocellular Cancer